Abstract
bcl-2 protein (BCL-2) expression was immunohistochemically studied in 140 varied central nervous system tumors. The protein was most frequently expressed in neuronomas and ependymomas, and in normal ependymal cells and Schwann cells. Most pituitary adenomas could be classified into one of two subgroups, diffusely positive or diffusely negative tumors, while BCL-2 localized heterogeneously in normal pituitary glands. Although the protein was not detected in normal astrocytes, it was positive in reactive hypertrophic astrocytes observed in various pathological conditions. Similarly, astrocytic tumor cells often expressed BCL-2. Since lowgrade astrocytomas more often exhibited the protein than malignant gliomas, the degree of BCL-2 expression appeared to be related to the degree of malignancy of the gliomas. On the other hand, 7 out of 17 recurrent gliomas and medulloblastomas showed an increase in the frequency of protein expression compared with specimens from initial treatments. One recurrent astrocytic tumor which demonstrated anaplastic change showed a decrease in the frequency of BCL-2-positive cells. It is concluded that the frequency of BCL-2 expression in CNS tumors is increased when the non-neoplastic counterparts of the tumors exhibit the protein. Although it has been reported that overexpression of BCL-2 protects cells from damage by radiation and/or chemotherapy, we could not find any significant relationship between the degree of BCL-2 expression and the length of survival of patients with glioblastomas or medulloblastomas.
Similar content being viewed by others
References
Allsopp TE, Wyatt S, Paterson HF, Davies AM (1993) The proto-oncogene bcl-2 can selectively rescue neurotrophic factor-dependent neurons from apoptosis. Cell 73: 295–307
Batistatou A, Merry DE, Korsmeyer SJ, Greene LA (1993) Bcl-2 affects survival but not neuronal differentiation of PC12 cells. J Neurosci 13: 4422–4428
Castle VP, Heidelberger KP, Bromberg J, Ou X, Dole M, Nunez G (1993) Expression of the apoptosis-suppressing protein bcl-2 in neuroblastomas is associated with unfavorable histology and N-myc amplification. Am J Pathol 143: 1543–1550
Cattoretti G, Pileri S, Parravicini C, Becker MHG, Poggi S, Bifulco C, Key G, D'Amato L, Sabattini E, Feudale E, Reynolds F, Gerdes J, Rilke F (1993) Antigen unmasking on formalinfixed paraffin-embedded tissue sections. J Pathol 171: 83–98
Drewett N, Jacobi JA, Willgoss DA, Lloyd HM (1993) Apoptosis in the anterior pituitary gland of the rat: studies with estrogen and bromocriptine. Neuroendocrinology 57: 89–95
Dubois-Dauphin M, Frankowski H, Tujimoto Y, Huarte J, Martinou J-C (1994) Neonatal motoneurons overexpressing the bcl-2 protooncogene in transgenic mice are protected from axotomy-induced cell death. Proc Natl Acad Sci USA 91: 3309–3313
Fisher TC, Milner AE, Gregory CD, Jackman AL, Aherne W, Hartley JA, Dive C, Hickman JA (1993) bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res 53: 3321–3326
Hanada M, Krajewski S, Tanaka S, Cazals-Hatem D, Spengler BA, Ross RA, Biedler JL, Reed JC (1993) Regulation of bcl-2 oncoprotein levels with differentiation of human neuroblastoma cells. Cancer Res 53: 4978–4986
Hockenbery DM, Numez G, Milliman C, Schreiber RD, Korsmeyer SJ (1990) Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334–336
Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ (1991) BCL-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88: 6961–6965
Hockenbery DM, Oltvai ZN, Yin X-M, Milliman CL, Korsmeyer S (1993) Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75: 241–251
Jacobson MD, Burne JF, King MP, Miyashita T, Reed JC, Raff MC (1993) Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature 361: 365–369
Kane DJ, Sarafian TA, Anton R, Hahn H, Gralla EB, Valentine JS, Oerd T, Bredesen DE (1993) Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science 262: 1274–1277
Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC (1993) Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 53: 4701–4714
LeBrun DP, Warnke RA, Cleary ML (1993) Expression of bcl-2 in fetal tissues suggests a role in morphogenesis. Am J Pathol 142: 743–753
Leoncini L, Del Vecchio MT, Megha T, Barbini P, Galieni P, Pileri S, Sabattini E, Gherlinzoni F, Tosi P, Kraft R, Cottier H (1993) Correlations between apoptotic and proliferative indices in malignant non-Hodgkin's lymphomas. Am J Pathol 142: 755–763
Lu Q-L, Elia G, Lucas S, Thomas AJ (1993) Bcl-2 proto-oncogene expression in Epstein-Barr virus associated nasopharyngeal carcinoma. Int J Cancer 53: 29–35
Lu Q-L, Poulsom R, Wong L, Hanby AM (1993) Bcl-2 expression in adult and embryonic non-haematopoietic tissues. J Pathol 169: 431–437
McDonnel TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh J-T, Tu S-M, Campbell ML (1992) Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940–6944
Nakasu S, Matsumura K, Nioka H, Handa J (1994) Lectin binding and bcl-2 protein expression in craniopharyngiomas. Neurol Med Chir (Tokyo) 34: 429–435
Reed JC, Meister L, Tanaka S, Cuddy M, Yum S, Geyer C, Pleasure D (1991) Differential expression of bcl-2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Res 51: 6529–6538
Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ (1991) Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 67: 879–888
Shi S-R, Key ME, Kalra KL (1991) Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39: 741–748
Strasser A, Harris AW, Cory S (1991) bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell 67: 889–899
Tsujimoto Y, Croce C (1986) Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 83: 5214–5218
Walton MI, Whysong D, O'Connor PM, Hockenbery D, Korsmeyer SJ, Kohn KW (1993) Constitutive expression of human bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res 53: 1853–1861
Williams GT, Smith CA (1993) Molecular regulation of apoptosis: genetic controls on cell death. Cell 74: 777–779
Wyllie AH, Kerr JFR, Currie AR (1980) Cell death: the significance of apoptosis. Int Rev Cytol 68: 251–306
Zhong L-T, Sarafian T, Kane D, Charles AC, Mah SP, Edwards RH, Bredesen DE (1993) bcl-2 inhibits death of central neural cells induced by multiple agents. Proc Natl Acad Sci USA 90: 4533–4537
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nakasu, S., Nakasu, Y., Nioka, H. et al. bcl-2 protein expression in tumors of the central nervous system. Acta Neuropathol 88, 520–526 (1994). https://doi.org/10.1007/BF00296488
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00296488